Balsm Alofoq Medical Company (9620) fair value: what the stock is really worth
As of Oct 27, 2026: fair value (intrinsic value) of Balsm Alofoq Medical Company stock SAR 12.19, price SAR 22.00, upside -44.6%, quality 31 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.
How to read this chart
22‑month range 22.00 SAR – 41.00 SAR · fair‑value band 8.39 SAR – 15.85 SAR · the 22.00 SAR price screens above the 12.19 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.
Follow Balsm Alofoq Medical in your weekly email
Every Wednesday you see whether Balsm Alofoq Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Balsm Alofoq Medical Company provides various services and solutions for medical sector in the Kingdom of Saudi Arabia.
Show moreShow less
It is involved in operation of hospitals, specialized medical complexes, general medical complexes, medical clinics, day surgery centers, and medical laboratories; wholesale and retail of medical devices, equipment, and supplies; operation of hazardous waste treatment facilities; medical equipment and product warehouses; social welfare institutions; identification and distribution of social assistance; daycare for people with special needs; adoption services; transportation of hazardous medical waste; installation of machinery and equipment; and counseling for families and individuals.
Balsm Alofoq Medical Company was incorporated in 2012 and is based in Buraydah, the Kingdom of Saudi Arabia.
Stock analysis
Balsm Alofoq Medical Company (9620) currently trades at 22.00 SAR, while our model-based Fair Value estimate is 12.19 SAR, 44.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 19.93 SAR per share, and 3 of the 15 models we run sit above the 22.00 SAR price.
Bear case: the Asset-Based group reads lowest at 6.34 SAR, and 12 of the 15 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 8.39 SAR (bear) to 15.85 SAR (bull), the price of 22.00 SAR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Balsm Alofoq Medical Company reported revenue of 20.4M SAR in FY2025 versus 17.0M SAR in FY2022, a compound +6.2%/yr. Reported net income was 2.0M SAR in FY2025, compounding −17.6%/yr from FY2022.
Key figures
Market cap 54.8M SAR (≈ $14.6M) Micro · P/E ratio 38.6 · P/S ratio 2.49 · EPS (TTM) 0.5700 SAR · Dividend yield 5.5% · Net margin 6.5% · Return on equity 4.6% · Return on assets (EBIT) 17.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (medium confidence).
What moves the price
The share trades about 27% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −45%, 9620 screens richer than that median.
Fair Value models
Bear8.39 SARFair Value 12.19 SARBull15.85 SAR
Price 22.00 SAR · Upside -44.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.4732 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income9.58 SAR9.93 SAR10.64 SAR73
EPV12.16 SAR13.30 SAR14.27 SAR70
ROIC Compounder12.16 SAR13.63 SAR15.33 SAR67
All 15 models by family
Earnings-Based
Graham-Dodd5.35 SAR13.70 SAR17.82 SAR62
PEG = 1.02.56 SAR3.66 SAR4.76 SAR55
EPV12.16 SAR13.30 SAR14.27 SAR70
Dividend Discount
Gordon GGM9.87 SAR17.61 SAR26.61 SAR64
DDM Multi-Stage9.87 SAR14.48 SAR18.99 SAR64
Multiples
P/E Multiple12.98 SAR17.31 SAR21.64 SAR63
P/S Multiple10.03 SAR13.38 SAR16.72 SAR58
P/B Multiple41.71 SAR55.61 SAR69.51 SAR55
EV/EBIT19.68 SAR24.04 SAR28.41 SAR63
EV/EBITDA22.33 SAR27.58 SAR32.84 SAR64
EV/Revenue15.93 SAR19.93 SAR23.94 SAR52
Asset-Based
NCAV (Graham)4.18 SAR6.34 SAR7.92 SAR52
Economic Profit
Residual Income9.58 SAR9.93 SAR10.64 SAR73
ROIC Compounder12.16 SAR13.63 SAR15.33 SAR67
Growth Earnings
Growth-Adj P/E10.04 SAR14.34 SAR18.65 SAR65
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.34/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+2.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−14.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−19.9%
Dividend (yield on the price)5.5%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 13%
Compare Balsm Alofoq Medical Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 327 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−44.6% · Below median
Profitability
Return on equity (12 months)4.6% · Above median
Return on assets5.5% · Above median
Net margin (12 months)6.5% · Above median
Operating margin (12 months)5.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)17.0% · Above median
Dividend yield (12 months)5.5% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)38.6× · Pricier than median
P/B1.77× · Cheaper than median
P/S (12 months)2.49× · Cheaper than median
EV/EBITDA16.0× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 7
FUTURE (revenue growth)85· sector 33
PAST (return on equity)18· sector 16
HEALTH (low debt)0· sector 98
DIVIDEND (yield)100· sector 35
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Balsm Alofoq Medical Company Fair Value". https://www.fairvalue-calculator.com/stock/9620
Frequently asked questions
Is Balsm Alofoq Medical Company (9620) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of 12.19 SAR versus a price of 22.00 SAR, about −45% upside (overvalued).
What is the fair value of 9620?
Our model-based fair value for Balsm Alofoq Medical Company is 12.19 SAR (as of Oct 29, 2026), built from audited fundamentals. The current price: 22.00 SAR.
What is the quality score of 9620?
Balsm Alofoq Medical Company has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Balsm Alofoq Medical Company (9620)?
Our model-based price target is the fair value of 12.19 SAR (as of Oct 29, 2026) from 15 valuation models. Cautious scenario 8.39 SAR, optimistic scenario 15.85 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Balsm Alofoq Medical Company stock forecast for 2026?
Our models put fair value at 12.19 SAR, about −45% upside versus a price of 22.00 SAR (overvalued). Cautious scenario 8.39 SAR, optimistic scenario 15.85 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Balsm Alofoq Medical Company (9620)?
Balsm Alofoq Medical Company reported trailing-twelve-month revenue of about 22.0M SAR (latest available figure, as of Oct 29, 2026).
Does Balsm Alofoq Medical Company pay a dividend?
Balsm Alofoq Medical Company currently shows a dividend yield of 5.45% relative to its recent price (as of Oct 29, 2026).
What is the intrinsic value of Balsm Alofoq Medical Company (9620)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Balsm Alofoq Medical Company it is 12.19 SAR per share (as of Oct 29, 2026), against a price of 22.00 SAR. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Balsm Alofoq Medical Company stock overvalued or undervalued in 2026?
As of Oct 29, 2026, 9620 trades above its calculated fair value: price 22.00 SAR, fair value 12.19 SAR, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9620?
No. The price is what the market pays today (22.00 SAR); the fair value is what the company's own numbers justify (12.19 SAR). For Balsm Alofoq Medical Company the two are 9.81 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Balsm Alofoq Medical Company worth?
The market values Balsm Alofoq Medical Company at about 54.8M SAR (market capitalisation, as of Oct 29, 2026). Per share that is 22.00 SAR; our models calculate a fair value of 12.19 SAR per share.
What do the bullish and bearish scenarios say about 9620?
Our models span a range for Balsm Alofoq Medical Company: cautious scenario 8.39 SAR, base 12.19 SAR, optimistic 15.85 SAR per share (as of Oct 29, 2026, price 22.00 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9620?
Balsm Alofoq Medical Company trades at a price-to-earnings ratio of 38.6 (as of Oct 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 12.19 SAR is built from several models across several years. Other multiples: P/B 1.8, P/S 2.5, EV/EBITDA 16.0.
How solid is the balance sheet of Balsm Alofoq Medical Company (9620)?
Balance-sheet figures for Balsm Alofoq Medical Company (as of Oct 29, 2026): return on equity 4.6%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 9620 from its 52-week high?
Balsm Alofoq Medical Company trades at 22.00 SAR, about 27% below its 52-week high of 30.10 SAR and at the low of 22.00 SAR (as of Oct 27, 2026). Distance from the high says nothing about value: that is what the fair value of 12.19 SAR is for.
Which stocks are comparable to Balsm Alofoq Medical Company?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Balsm Alofoq Medical Company stock attractive at the current price?
The data as of Oct 29, 2026: price 22.00 SAR, calculated fair value 12.19 SAR (−45%), Quality Score 31/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9620 calculated?
We run Balsm Alofoq Medical Company through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 12.19 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Balsm Alofoq Medical Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Balsm Alofoq Medical Company (9620)?
The closing price on Oct 27, 2026 was 22.00 SAR. Our model-based fair value is 12.19 SAR, about −45% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Balsm Alofoq Medical Company right now?
The price sits above even our optimistic bull case (15.85 SAR). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (8.39 SAR to 15.85 SAR) leaves room in how you read the outcome.
Key figures of Balsm Alofoq Medical Company
How large is the market capitalisation of Balsm Alofoq Medical Company (9620)?
The market capitalisation of Balsm Alofoq Medical Company is 54.8M SAR (≈ $14.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Balsm Alofoq Medical Company (9620)?
The price-to-sales ratio of Balsm Alofoq Medical Company is 2.49 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Balsm Alofoq Medical Company (9620)?
Earnings per share at Balsm Alofoq Medical Company are 0.5700 SAR (price ÷ EPS = P/E 38.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Balsm Alofoq Medical Company (9620)?
The dividend yield of Balsm Alofoq Medical Company is 5.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Balsm Alofoq Medical Company (9620)?
The net margin of Balsm Alofoq Medical Company is 6.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Balsm Alofoq Medical Company (9620)?
The return on equity (ROE) of Balsm Alofoq Medical Company is 4.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Balsm Alofoq Medical Company (9620)?
On an EBIT basis the return on assets of Balsm Alofoq Medical Company is 17.2% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Balsm Alofoq Medical Company (9620)?
The operating margin of Balsm Alofoq Medical Company is 5.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Balsm Alofoq Medical Company (9620)?
Revenue at Balsm Alofoq Medical Company is growing +17.0% versus a year earlier (3y avg +6.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Balsm Alofoq Medical Company (9620)?
Earnings per share at Balsm Alofoq Medical Company are growing −40.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Balsm Alofoq Medical Company (9620) generate?
The free cash flow of Balsm Alofoq Medical Company is −7.1M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Balsm Alofoq Medical Company (9620) hold?
Balsm Alofoq Medical Company holds more cash than debt, 16.4M SAR net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Balsm Alofoq Medical Company in the live analysis
One click puts Balsm Alofoq Medical Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 29, 2026